In expanded-ataxin-3 CHO cells, divalproex sodium improved the PrestoBlue viability readout relative to DMSO at 100–1000 μmol/L after 2 or 24 h. High-concentration vehicle effects complicate the 2 h result. In a separate HEK293 model, 10 μmol/L for 24 h did not significantly reduce expanded-ataxin-3 aggregation. These model-specific responses do not demonstrate disease modification. [1]
Histone H3 acetylation in ataxin-3-expressing HEK293 cells
Cell-based study · HEK293 cells transiently expressing normal ataxin-3 (15Q) or expanded ataxin-3 (77Q) [1]
Acetylated H3 normalized to total H3 increased significantly after 24 h versus DMSO. Earlier increases were trends without significance. This is a cellular pharmacodynamic endpoint, not a direct HDAC activity assay.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.3 mmol/L
- Exposure duration
- 6, 12 and 24 h; treatment initiated 48 h after transfection
- Method
- Addition to cultured cells
- Vehicle
- DMSO; DMSO-only controls
- Reported limits
- Final DMSO percentage and tested lot analytical identity are not specified in the retrieved text.
Methods and source locations
Compound reported in the paper: Divalproex sodium; Compound label in the paper: Divalproex
Reported findings apply to the study material and these cell models; they do not establish Adooq lot performance.
Section 3.1; Figure 1; Sections 2.1, 2.2, 2.4, 2.7
Acetylated histone H3 / total histone H3: Western blot; total H3 and ataxin-3 controls; Student t-test — Section 3.1; Figure 1 image and caption; Sections 2.4, 2.7
Viability response in expanded-ataxin-3 CHO cells
Cell-based study · CHO cells stably expressing expanded ataxin-3 (77Q) [1]
PrestoBlue fluorescence supported a viability benefit at 100–1000 μmol/L relative to DMSO after 2 or 24 h. At 2 h, the highest concentration also reduced signal relative to untreated cells, with a greater reduction in the DMSO control. Vehicle effects limit interpretation of protection.
Literature-Reported Treatment Conditions
- Treatment concentration
- Reported rescue range: 100–1000 μmol/L; a wider dilution series is plotted in Figure 5
- Exposure duration
- 2 and 24 h
- Method
- Addition to cultured cells
- Vehicle
- DMSO; DMSO-only controls
- Reported limits
- Final DMSO percentage and tested lot analytical identity are not specified in the retrieved text.
Methods and source locations
Compound reported in the paper: Divalproex sodium; Compound label in the paper: Divalproex
Reported findings apply to the study material and these cell models; they do not establish Adooq lot performance.
Section 3.5; Figure 5; Sections 2.1, 2.2, 2.6, 2.7
PrestoBlue fluorescence normalized to untreated cells or DMSO: PrestoBlue fluorescence; untreated and DMSO comparators; two-way ANOVA — Section 3.5; Figure 5A–D and caption; Sections 2.6, 2.7
No significant reduction of expanded ataxin-3 aggregation
Cell-based study · HEK293 cells expressing expanded ataxin-3 (148Q), with normal ataxin-3 (15Q) as comparator [1]
Divalproex sodium did not significantly reduce SDS-resistant expanded ataxin-3 aggregates relative to DMSO or untreated controls under the reported conditions.
Literature-Reported Treatment Conditions
- Treatment concentration
- 10 μmol/L
- Exposure duration
- 24 h, as specified in Figure 3 caption
- Method
- Addition to cultured cells
- Vehicle
- DMSO; DMSO-only controls
- Reported limits
- Final DMSO percentage and tested lot analytical identity are not specified in the retrieved text.
Methods and source locations
Compound reported in the paper: Divalproex sodium; Compound label in the paper: Divalproex
Reported findings apply to the study material and these cell models; they do not establish Adooq lot performance.
Section 3.3; Figure 3; Sections 2.2, 2.5, 2.7
SDS-resistant ataxin-3 aggregate signal: Filter trap assay; normal-repeat and expanded-repeat constructs; DMSO and untreated controls; Student t-test — Section 3.3; Figure 3 image and caption; Sections 2.5, 2.7